PeptideStack
5.2kquestions
20kanswers
220users

How long does orforglipron stay within specification at minus 80 °C once reconstituted?

Asked 13 May 2026Modified 6 days agoViewed 3.2k times
6

What I am working with: orforglipron · minus 80 °C.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What is the correct sequence, and where is the step that people usually skip?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
RP
askedravi_pillai12k1713 May 2026
7What temperature, and for how long? Both are needed before anyone can say anything useful. – per_haugen 4 months ago
8Do you know the residual moisture? It predicts this better than any date does. – rota_site 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
10

Accepted answer

Whatever the refrigerated figure is, freezing does not simply extend it. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. A frozen solution is not a slow solution: ice excludes solute, so the unfrozen fraction concentrates, the pH of the buffer shifts as one component crystallises first, and the damage happens during the transitions rather than during the hold. "Within specification" also needs a specification: purity, content, or both, and at what limit. Without that the question has no numerical answer at all.

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Reported and extrapolated stability by condition

StateConditionUsable windowBasis
Lyophilised solid−20 °C, sealed, dry24–36 monthsSupplier guidance
Lyophilised solid2–8 °C, sealed12–24 monthsSupplier guidance
Lyophilised solid25 °C, sealed4–8 weeksExtrapolated (Arrhenius)
Lyophilised solid40 °C, sealed1–2 weeksExtrapolated
Solution, preserved2–8 °C28 daysUSP microbiological convention
Solution, preserved25 °C3–7 daysExtrapolated
Solution, unpreserved2–8 °C24 hoursUSP microbiological convention

Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.

Put another way, deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
MO
answered · acceptedmarta_okonkwo190k25814 Jul 2026
2This should be linked from the help pages. – stopper_core 2 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
4

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

To be exact about it, freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
HN
answeredhalvard_ness69k4726 May 2026
3

In practice, aggregation is a physical process and is the one most often caused by handling rather than by time.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

shareimprove this answerflag
HN
answeredhalvard_ness69k4725 Jun 2026
1

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
DW
answeredDr_Elias_Weiss25k2724 Jul 2026
4This should be in the site help pages rather than buried in an answer. – kwn_analytical 23 days ago
3Confirming that opening a cold vial in a humid room is a genuinely bad idea. – s_bhattacharya 9 months ago
add a comment
-1

In practice, asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Sequence decides which pathways are even available. Check the residues.

edited 23 Jun 2026 by Dr_Otto_Lindqvist — expanded the table to cover the lower concentration

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist72k5815 Jun 2026
6Worth adding that residual moisture predicts this better than any printed date. – gradient_slope 4 months ago
7The desiccant point is under-appreciated and costs nothing to act on. – anja_hellstrom 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.